Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3836)
All Articles published online
|
Nov 21, 2006 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xie DR, Liang HL, Wang Y, Guo SS, Yang Q. Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006; 12(43): 6973-6981 [PMID: 17109519 DOI: 10.3748/wjg.v12.i43.6973] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i43/6973.htm |
| Number | Citing Articles |
| 1 |
Manuel Hidalgo, Albert Abad, Enrique Aranda, Luis Díez, Jaime Feliu, Carlos Gómez, Antonio Irigoyen, Rafael López, Fernando Rivera, Carmen Rubio, Javier Sastre, Josep Tabernero, Eduardo Díaz-Rubio. Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology 2009; 11(5): 290 doi: 10.1007/s12094-009-0357-3
|
| 2 |
JUN GONG, RICHARD TULI, ARVIND SHINDE, ANDREW E. HENDIFAR. Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology 2016; 4(3): 315 doi: 10.3892/mco.2015.716
|
| 3 |
Axel Kleespies, Ivan Ischenko, Martin E. Eichhorn, Hendrik Seeliger, Christiane Amendt, Ole Mantell, Karl-Walter Jauch, Christiane J. Bruns. Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine. Clinical Cancer Research 2008; 14(17): 5426 doi: 10.1158/1078-0432.CCR-07-5245
|
| 4 |
A Sultana, C Tudur Smith, D Cunningham, N Starling, J P Neoptolemos, P Ghaneh. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. British Journal of Cancer 2008; 99(1): 6 doi: 10.1038/sj.bjc.6604436
|
| 5 |
Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemotherapy and Pharmacology 2009; 64(2): 317 doi: 10.1007/s00280-008-0873-9
|
| 6 |
Emilio Bria, Michele Milella, Alain Gelibter, Federica Cuppone, Maria Simona Pino, Enzo Maria Ruggeri, Paolo Carlini, Cecilia Nisticò, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?. Cancer 2007; 110(3): 525 doi: 10.1002/cncr.22809
|
| 7 |
Sareh Seyedi, Valerie K. Harris, Stefania E. Kapsetaki, Shrinath Narayanan, Daniel Saha, Zachary Compton, Rezvan Yousefi, Alexander May, Efe Fakir, Amy M. Boddy, Marco Gerlinger, Christina Wu, Lida Mina, Silvie Huijben, Dawn H. Gouge, Luis Cisneros, Peter C. Ellsworth, Carlo C. Maley. Resistance Management for Cancer: Lessons from Farmers. Cancer Research 2024; 84(22): 3715 doi: 10.1158/0008-5472.CAN-23-3374
|
| 8 |
H. Oettle, U. Pelzer, J. Stieler, H. Riess. Adjuvante und palliative Therapie des Pankreaskarzinoms. Der Onkologe 2010; 16(6): 595 doi: 10.1007/s00761-010-1851-5
|
| 9 |
Christopher Paiji, V. Raman Muthusamy. Endoscopic Ultrasonography. 2024; : 223 doi: 10.1002/9781119697893.ch24
|
| 10 |
D. r. Xie, Q. Yang, D. l. Chen, Z. m. Jiang, Z. f. Bi, W. Ma, Y. d. Zhang. Gemcitabine-based Cytotoxic Doublets Chemotherapy for Advanced Pancreatic Cancer: Updated Subgroup Meta-analyses of Overall Survival. Japanese Journal of Clinical Oncology 2010; 40(5): 432 doi: 10.1093/jjco/hyp198
|
| 11 |
Rei Suzuki, Atsushi Irisawa, Manoop S. Bhutani. Endoscopic Ultrasound-Guided Oncologic Therapy for Pancreatic Cancer. Diagnostic and Therapeutic Endoscopy 2013; 2013: 1 doi: 10.1155/2013/157581
|
| 12 |
Kharat Aditi, Tan Chia Jie, Saeteaw Manit, Chhibber Anindit, Biskupiak Joseph, Veettil Sajesh K, Chaiyakunapruk Nathorn. Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials. Annals of Pancreatic Disorders and Treatment 2022; 4(1): 001 doi: 10.17352/apdt.000008
|
| 13 |
Min Xuan, Na Li, Chunyan Wu. A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer. Clinics 2024; 79: 100348 doi: 10.1016/j.clinsp.2024.100348
|
| 14 |
Fenghua Liu, Yong Tang, Junwei Sun, Zhanna Yuan, Shasha Li, Jun Sheng, He Ren, Jihui Hao, James M. Wright. Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2012; 7(7): e40847 doi: 10.1371/journal.pone.0040847
|
| 15 |
Ying-Jui Chao, Edgar D Sy, Hui-Ping Hsu, Yan-Shen Shan. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. BMC Surgery 2014; 14(1) doi: 10.1186/1471-2482-14-72
|
| 16 |
Hongxu Chen, Xiang Lan, Menggang Liu, Bo Zhou, Baoling Wang, Ping Chen. Direct TGF‐β1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Cell Biology International 2013; 37(5): 478 doi: 10.1002/cbin.10067
|
| 17 |
Amit Dang, Surendar Chidirala, Prashanth Veeranki, B.N. Vallish. A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. Reviews on Recent Clinical Trials 2021; 16(2): 180 doi: 10.2174/1574887115666200902111510
|
| 18 |
George Fountzilas, Mattheos Bobos, Anna Kalogera-Fountzila, Nikolaos Xiros, Samuel Murray, Helena Linardou, Georgia Karayannopoulou, Angelos K. Koutras, Dimitrios Bafaloukos, Epaminondas Samantas, Christos Christodoulou, Theofanis Economopoulos, Konstantine T. Kalogeras, Paris Kosmidis. Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation. Cancer Investigation 2008; 26(8): 784 doi: 10.1080/07357900801918611
|
| 19 |
Guoqing Ouyang, Zhipeng Liu, Shengfu Huang, Qianglong Li, Li Xiong, Xiongying Miao, Yu Wen. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World Journal of Surgical Oncology 2016; 14(1) doi: 10.1186/s12957-016-0813-9
|
| 20 |
Emmanuel Mitry, Pascal Hammel, Gaël Deplanque, Françoise Mornex, Philippe Levy, Jean-François Seitz, Alain Moussy, Jean-Pierre Kinet, Olivier Hermine, Philippe Rougier, Eric Raymond. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2010; 66(2): 395 doi: 10.1007/s00280-010-1299-8
|
| 21 |
Carlos Gómez-Martín, Manuel Hidalgo, Josep Tabernero, Dolores Isla. SEOM clinical guidelines for the treatment of pancreatic cancer. Clinical and Translational Oncology 2011; 13(8): 528 doi: 10.1007/s12094-011-0693-y
|
| 22 |
Wang Zhongmin, Liu Yu, Liu Fenju, Chen Kemin, Huang Gang. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. European Radiology 2010; 20(7): 1786 doi: 10.1007/s00330-009-1703-0
|
| 23 |
Zhendong Jin, Kenneth J. Chang. Endoscopic Ultrasound-Guided Fiducial Markers and Brachytherapy. Gastrointestinal Endoscopy Clinics of North America 2012; 22(2): 325 doi: 10.1016/j.giec.2012.04.012
|
| 24 |
A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, F. Lofts, J. Sgouros, E. Gardiner, K. Wedgwood, C. Ettelaie, G. Bozas. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer 2012; 48(9): 1283 doi: 10.1016/j.ejca.2011.10.017
|
| 25 |
Kourosh F. Ghassemi, V. Raman Muthusamy. Endoscopic Ultrasonography. 2016; : 239 doi: 10.1002/9781118781067.ch25
|
| 26 |
Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim. Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis. Cancer Research and Treatment 2008; 40(1): 22 doi: 10.4143/crt.2008.40.1.22
|
| 27 |
Fernando Rivera, Sara López-Tarruella, Ma Eugenia Vega-Villegas, Matilde Salcedo. Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treatment Reviews 2009; 35(4): 335 doi: 10.1016/j.ctrv.2008.11.007
|
| 28 |
Eileen M. O’Reilly, Ghassan K. Abou-Alfa. Cytotoxic Therapy for Advanced Pancreatic Adenocarcinoma. Seminars in Oncology 2007; 34(4): 347 doi: 10.1053/j.seminoncol.2007.05.009
|
| 29 |
Volker Heinemann, Stefan Boeck, Axel Hinke, Roberto Labianca, Christophe Louvet. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8(1) doi: 10.1186/1471-2407-8-82
|
| 30 |
Sridhar P. Susheela, Swaroop Revannasiddaiah, Ajaikumar Basavalingaiah. Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury. Journal of Radiotherapy 2014; 2014: 1 doi: 10.1155/2014/489824
|
| 31 |
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody. Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2014; 9(8): e104346 doi: 10.1371/journal.pone.0104346
|